Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease.

Faura J, Bustamante A, Penalba A, Giralt D, Simats A, Martínez-Sáez E, Alcolea D, Fortea J, Lleó A, Teunissen CE, van der Flier WM, Ibañez L, Harari O, Cruchaga C, Hernández-Guillamón M, Delgado P, Montaner J.

J Alzheimers Dis. 2020;73(4):1585-1595. doi: 10.3233/JAD-190753.

PMID:
31958084
2.

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2020 Jan 18. doi: 10.1007/s00401-019-02107-8. [Epub ahead of print]

PMID:
31955222
3.

Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease.

Cantero JL, Atienza M, Lage C, Zaborszky L, Vilaplana E, Lopez-Garcia S, Pozueta A, Rodriguez-Rodriguez E, Blesa R, Alcolea D, Lleo A, Sanchez-Juan P, Fortea J; Alzheimer’s Disease Neuroimaging Initiative.

Cereb Cortex. 2019 Dec 4. pii: bhz224. doi: 10.1093/cercor/bhz224. [Epub ahead of print]

PMID:
31799623
4.

APP-derived peptides reflect neurodegeneration in frontotemporal dementia.

Illán-Gala I, Pegueroles J, Montal V, Alcolea D, Vilaplana E, Bejanin A, Borrego-Écija S, Sampedro F, Subirana A, Sánchez-Saudinós MB, Rojas-García R, Vanderstichele H, Blesa R, Clarimón J, Antonell A, Lladó A, Sánchez-Valle R, Fortea J, Lleó A.

Ann Clin Transl Neurol. 2019 Dec;6(12):2518-2530. doi: 10.1002/acn3.50948. Epub 2019 Dec 2.

5.

Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It.

Puente A, Fortea JI, Del Pozo C, Huelin P, Cagigal ML, Serrano M, Cabezas J, Arias Loste MT, Iruzubieta P, Cuadrado A, Llerena S, Lopez C, Fábrega E, Crespo J.

Cells. 2019 Nov 24;8(12). pii: E1506. doi: 10.3390/cells8121506. Review.

6.

Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain.

Crespo J, Cuadrado A, Perelló C, Cabezas J, Llerena S, Llorca J, Cedillo S, Llop E, Escudero MD, Hernández Conde M, Puchades L, Redondo C, Fortea JI, Gil de Miguel A, Serra MA, Lazarus JV, Calleja JL.

J Viral Hepat. 2020 Apr;27(4):360-370. doi: 10.1111/jvh.13238. Epub 2019 Dec 6.

PMID:
31755634
7.

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?

Veerabhadrappa B, Delaby C, Hirtz C, Vialaret J, Alcolea D, Lleó A, Fortea J, Santosh MS, Choubey S, Lehmann S.

Crit Rev Clin Lab Sci. 2020 Mar;57(2):99-113. doi: 10.1080/10408363.2019.1678011. Epub 2019 Oct 29.

PMID:
31661652
8.

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.

Alcolea D, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I, Ribosa-Nogué R, Sala I, Sánchez-Saudinós MB, Videla L, Subirana A, Benejam B, Valldeneu S, Fernández S, Estellés T, Altuna M, Santos-Santos M, García-Losada L, Bejanin A, Pegueroles J, Montal V, Vilaplana E, Belbin O, Dols-Icardo O, Sirisi S, Querol-Vilaseca M, Cervera-Carles L, Muñoz L, Núñez R, Torres S, Camacho MV, Carrió I, Giménez S, Delaby C, Rojas-Garcia R, Turon-Sans J, Pagonabarraga J, Jiménez A, Blesa R, Fortea J, Lleó A.

Alzheimers Dement (N Y). 2019 Oct 14;5:597-609. doi: 10.1016/j.trci.2019.09.005. eCollection 2019.

9.

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors.

Powers RK, Culp-Hill R, Ludwig MP, Smith KP, Waugh KA, Minter R, Tuttle KD, Lewis HC, Rachubinski AL, Granrath RE, Carmona-Iragui M, Wilkerson RB, Kahn DE, Joshi M, Lleó A, Blesa R, Fortea J, D'Alessandro A, Costello JC, Sullivan KD, Espinosa JM.

Nat Commun. 2019 Oct 18;10(1):4766. doi: 10.1038/s41467-019-12739-9.

10.

Epidemiology and clinical course of hepatitis A in Cantabria before and after the epidemic outbreak of June 2016.

Fortea JI, Fernandez González M, Samaniego Vega L, Puente Á, Cuadrado A, Cabezas J, Llerena S, Sáez López A, Crespo J, Fábrega E.

Rev Clin Esp. 2019 Oct 10. pii: S0014-2565(19)30225-5. doi: 10.1016/j.rce.2019.08.005. [Epub ahead of print] English, Spanish.

PMID:
31606120
11.

Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review.

Hamburg S, Lowe B, Startin CM, Padilla C, Coppus A, Silverman W, Fortea J, Zaman S, Head E, Handen BL, Lott I, Song W, Strydom A.

J Neurodev Disord. 2019 Aug 30;11(1):20. doi: 10.1186/s11689-019-9279-8. Review.

12.

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Alcolea D, Pegueroles J, Muñoz L, Camacho V, López-Mora D, Fernández-León A, Le Bastard N, Huyck E, Nadal A, Olmedo V, Sampedro F, Montal V, Vilaplana E, Clarimón J, Blesa R, Fortea J, Lleó A.

Ann Clin Transl Neurol. 2019 Sep;6(9):1815-1824. doi: 10.1002/acn3.50873. Epub 2019 Aug 28.

13.

Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy.

Puente A, Fortea JI, Posadas M, Garcia Blanco A, Rasines L, Cabezas J, Arias Loste MT, Llerena S, Iruzubieta P, Fábrega E, Crespo J.

J Clin Med. 2019 Aug 17;8(8). pii: E1242. doi: 10.3390/jcm8081242.

14.

Number of Antibody-verified Eplet in HLA-C Locus as an Independent Factor of T-cell-Mediated Rejection After Liver Transplantation.

Guiral S, Segundo DS, Irure J, Casafont F, Fortea JI, Puente Á, López-Hoyos M, Crespo J, Fabrega E.

Transplantation. 2020 Mar;104(3):562-567. doi: 10.1097/TP.0000000000002921.

PMID:
31403556
15.

Exosome release and cargo in Down syndrome.

Hamlett ED, LaRosa A, Mufson EJ, Fortea J, Ledreux A, Granholm AC.

Dev Neurobiol. 2019 Jul;79(7):639-655. doi: 10.1002/dneu.22712. Epub 2019 Aug 6. Review.

PMID:
31347291
16.

Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis.

Esteve P, Rueda-Carrasco J, Inés Mateo M, Martin-Bermejo MJ, Draffin J, Pereyra G, Sandonís Á, Crespo I, Moreno I, Aso E, Garcia-Esparcia P, Gomez-Tortosa E, Rábano A, Fortea J, Alcolea D, Lleo A, Heneka MT, Valpuesta JM, Esteban JA, Ferrer I, Domínguez M, Bovolenta P.

Nat Neurosci. 2019 Aug;22(8):1258-1268. doi: 10.1038/s41593-019-0432-1. Epub 2019 Jul 15.

PMID:
31308530
17.

Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis.

Carmona-Iragui M, Videla L, Lleó A, Fortea J.

Dev Neurobiol. 2019 Jul;79(7):716-737. doi: 10.1002/dneu.22709. Epub 2019 Aug 5. Review.

PMID:
31278851
18.

Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.

Tort-Merino A, Olives J, León M, Peñaloza C, Valech N, Santos-Santos MA, Càmara E, Grönholm-Nyman P, Martínez-Lage P, Fortea J, Molinuevo JL, Sánchez-Valle R, Laine M, Rodríguez-Fornells A, Rami L.

J Alzheimers Dis. 2019;70(1):211-225. doi: 10.3233/JAD-190046.

PMID:
31177219
19.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27. Erratum in: Acta Neuropathol. 2020 Jan 18;:.

20.

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.

Morenas-Rodríguez E, Alcolea D, Suárez-Calvet M, Muñoz-Llahuna L, Vilaplana E, Sala I, Subirana A, Querol-Vilaseca M, Carmona-Iragui M, Illán-Gala I, Ribosa-Nogué R, Blesa R, Haass C, Fortea J, Lleó A.

Sci Rep. 2019 May 24;9(1):7803. doi: 10.1038/s41598-019-44173-8.

21.

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter].

Orsatti L, Fortea J, Quaresma M.

Drug Des Devel Ther. 2019 Apr 12;13:1177-1178. doi: 10.2147/DDDT.S194065. eCollection 2019. No abstract available.

22.

LOXL2-A New Target in Antifibrogenic Therapy?

Puente A, Fortea JI, Cabezas J, Arias Loste MT, Iruzubieta P, Llerena S, Huelin P, Fábrega E, Crespo J.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1634. doi: 10.3390/ijms20071634. Review.

23.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
24.

Nanoscale structure of amyloid-β plaques in Alzheimer's disease.

Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, Nuñez-Llaves R, Luque-Cabecerans J, Muñoz-Llahuna L, Andilla J, Belbin O, Spires-Jones TL, Gelpi E, Clarimon J, Loza-Alvarez P, Fortea J, Lleó A.

Sci Rep. 2019 Mar 26;9(1):5181. doi: 10.1038/s41598-019-41443-3.

25.

Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy.

Illán-Gala I, Montal V, Borrego-Écija S, Vilaplana E, Pegueroles J, Alcolea D, Sánchez-Saudinós B, Clarimón J, Turón-Sans J, Bargalló N, González-Ortiz S, Rosen HJ, Gorno-Tempini ML, Miller BL, Lladó A, Rojas-García R, Blesa R, Sánchez-Valle R, Lleó A, Fortea J; Catalan Frontotemporal Dementia Initiative (CATFI) and the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI).

Brain. 2019 Apr 1;142(4):1121-1133. doi: 10.1093/brain/awz031.

26.

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, Rami L, Lladó A, Molinuevo JL, Tainta M, Clarimón J, Spires-Jones T, Blesa R, Fortea J, Martínez-Lage P, Sánchez-Valle R, Sabidó E, Bayés À, Belbin O.

Mol Cell Proteomics. 2019 Mar;18(3):546-560. doi: 10.1074/mcp.RA118.001290. Epub 2019 Jan 3.

27.

Alzheimer's disease in Down syndrome: An overlooked population for prevention trials.

Strydom A, Coppus A, Blesa R, Danek A, Fortea J, Hardy J, Levin J, Nuebling G, Rebillat AS, Ritchie C, van Duijn C, Zaman S, Zetterberg H.

Alzheimers Dement (N Y). 2018 Dec 13;4:703-713. doi: 10.1016/j.trci.2018.10.006. eCollection 2018. Review.

28.

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O'Bryant SE; International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association.

Alzheimers Dement. 2019 Feb;15(2):292-312. doi: 10.1016/j.jalz.2018.09.009. Epub 2018 Dec 13.

29.

Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding.

Fortea JI, Puente Á, Ruiz P, Ezcurra I, Vaquero J, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodríguez-Lope C, Huelin P, Casafont F, Fábrega E, Crespo J.

World J Clin Cases. 2018 Nov 6;6(13):611-623. doi: 10.12998/wjcc.v6.i13.611.

30.

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study.

Pegueroles J, Jiménez A, Vilaplana E, Montal V, Carmona-Iragui M, Pané A, Alcolea D, Videla L, Casajoana A, Clarimón J, Ortega E, Vidal J, Blesa R, Lleó A, Fortea J; Alzheimer's Disease Neuroimaging Initiative.

Oncotarget. 2018 Oct 5;9(78):34691-34698. doi: 10.18632/oncotarget.26162. eCollection 2018 Oct 5.

31.

Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings.

Giménez S, Videla L, Romero S, Benejam B, Clos S, Fernández S, Martínez M, Carmona-Iragui M, Antonijoan RM, Mayos M, Fortuna A, Peñacoba P, Plaza V, Osorio RS, Sharma RA, Bardés I, Rebillat AS, Lleó A, Blesa R, Videla S, Fortea J.

J Clin Sleep Med. 2018 Oct 15;14(10):1725-1733. doi: 10.5664/jcsm.7382.

32.

Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.

Alcolea D, Irwin DJ, Illán-Gala I, Muñoz L, Clarimón J, McMillan CT, Fortea J, Blesa R, Lee EB, Trojanowski JQ, Grossman M, Lleó A.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):180-186. doi: 10.1136/jnnp-2018-318993. Epub 2018 Oct 8.

33.

Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA.

Mandelli ML, Welch AE, Vilaplana E, Watson C, Battistella G, Brown JA, Possin KL, Hubbard HI, Miller ZA, Henry ML, Marx GA, Santos-Santos MA, Bajorek LP, Fortea J, Boxer A, Rabinovici G, Lee S, Deleon J, Rosen HJ, Miller BL, Seeley WW, Gorno-Tempini ML.

Cortex. 2018 Nov;108:252-264. doi: 10.1016/j.cortex.2018.08.002. Epub 2018 Aug 11.

34.

CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.

Illán-Gala I, Alcolea D, Montal V, Dols-Icardo O, Muñoz L, de Luna N, Turón-Sans J, Cortés-Vicente E, Sánchez-Saudinós MB, Subirana A, Sala I, Blesa R, Clarimón J, Fortea J, Rojas-García R, Lleó A.

Neurology. 2018 Oct 23;91(17):e1619-e1628. doi: 10.1212/WNL.0000000000006383. Epub 2018 Oct 5.

PMID:
30291183
35.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, Fox NC, Sanchez-Valle R, Grau-Rivera O, Gelpi E, Seelaar H, Papma JM, van Swieten JC, Hodges JR, Leyton CE, Piguet O, Rogalski EJ, Mesulam MM, Koric L, Nora K, Pariente J, Dickerson B, Mackenzie IR, Hsiung GR, Belliard S, Irwin DJ, Wolk DA, Grossman M, Jones M, Harris J, Mann D, Snowden JS, Chrem-Mendez P, Calandri IL, Amengual AA, Miguet-Alfonsi C, Magnin E, Magnani G, Santangelo R, Deramecourt V, Pasquier F, Mattsson N, Nilsson C, Hansson O, Keith J, Masellis M, Black SE, Matías-Guiu JA, Cabrera-Martin MN, Paquet C, Dumurgier J, Teichmann M, Sarazin M, Bottlaender M, Dubois B, Rowe CC, Villemagne VL, Vandenberghe R, Granadillo E, Teng E, Mendez M, Meyer PT, Frings L, Lleó A, Blesa R, Fortea J, Seo SW, Diehl-Schmid J, Grimmer T, Frederiksen KS, Sánchez-Juan P, Chételat G, Jansen W, Bouchard RW, Laforce RJ, Visser PJ, Ossenkoppele R.

Ann Neurol. 2018 Nov;84(5):729-740. doi: 10.1002/ana.25333.

36.

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease.

Perea JR, Lleó A, Alcolea D, Fortea J, Ávila J, Bolós M.

Front Neurosci. 2018 Sep 7;12:609. doi: 10.3389/fnins.2018.00609. eCollection 2018.

37.

Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species.

Oliveira F, Leuzy A, Castelhano J, Chiotis K, Hasselbalch SG, Rinne J, Mendonça A, Otto M, Lleó A, Santana I, Johansson J, Anderl-Straub S, Arnim C, Beer A, Blesa R, Fortea J, Sanna-Kaisa H, Portelius E, Pannee J, Zetterberg H, Blennow K, Moreira AP, Abrunhosa A, Nordberg A, Castelo-Branco M.

Neuroimage Clin. 2018 Aug 19;20:603-610. doi: 10.1016/j.nicl.2018.08.023. eCollection 2018.

38.

Challenges associated with biomarker-based classification systems for Alzheimer's disease.

Illán-Gala I, Pegueroles J, Montal V, Vilaplana E, Carmona-Iragui M, Alcolea D, Dickerson BC, Sánchez-Valle R, de Leon MJ, Blesa R, Lleó A, Fortea J.

Alzheimers Dement (Amst). 2018 Apr 21;10:346-357. doi: 10.1016/j.dadm.2018.03.004. eCollection 2018.

39.

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, Alcolea D, Pegueroles J, Muñoz L, Belbin O, de Leon MJ, Maceski AM, Hirtz C, Clarimón J, Videla S, Delaby C, Lehmann S, Blesa R, Lleó A.

Lancet Neurol. 2018 Oct;17(10):860-869. doi: 10.1016/S1474-4422(18)30285-0. Epub 2018 Aug 29.

PMID:
30172624
40.

Quality Care for People with Intellectual Disability and Advanced Dementia: Guidance on Service Provision.

McCarron M, McCallion P, Watchman K, Janicki MP, Coppus A, Service K, Fortea J, Hogan M, Reilly E, Stemp S.

J Palliat Med. 2018 Sep;21(9):1344-1352. doi: 10.1089/jpm.2017.0442. Epub 2018 Aug 21. Review.

PMID:
30129817
41.

Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey.

Fortea JI, Puente Á, Ezcurra I, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodríguez-Lope C, Huelin P, Casafont F, Fábrega E, Crespo J.

Dig Liver Dis. 2019 Jan;51(1):95-103. doi: 10.1016/j.dld.2018.06.003. Epub 2018 Jun 12.

PMID:
29960901
42.

Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.

Cuadrado A, Llerena S, Cobo C, Pallás JR, Mateo M, Cabezas J, Fortea JI, Alvarez S, Pellón R, Crespo J, Echevarría S, Ayesa R, Setién E, Lopez-Hoyos M, Crespo-Facorro B, Agüero J, Chueca N, Garcia F, Calleja JL, Crespo J.

Am J Gastroenterol. 2018 Nov;113(11):1639-1648. doi: 10.1038/s41395-018-0157-x. Epub 2018 Jun 27.

PMID:
29946175
43.

Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats - Improving Yield and Reproducibility.

Fortea JI, Fernández-Mena C, Puerto M, Ripoll C, Almagro J, Bañares J, Bellón JM, Bañares R, Vaquero J.

Sci Rep. 2018 Jun 15;8(1):9163. doi: 10.1038/s41598-018-27427-9.

44.

Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation.

Morenas-Rodríguez E, Sala I, Subirana A, Pascual-Goñi E, Sánchez-Saudinós MB, Alcolea D, Illán-Gala I, Carmona-Iragui M, Ribosa-Nogué R, Camacho V, Blesa R, Fortea J, Lleó A.

J Alzheimers Dis. 2018;64(2):505-513. doi: 10.3233/JAD-180167.

PMID:
29889064
45.

Supporting advanced dementia in people with Down syndrome and other intellectual disability: consensus statement of the International Summit on Intellectual Disability and Dementia.

McCarron M, McCallion P, Coppus A, Fortea J, Stemp S, Janicki M, Wtachman K.

J Intellect Disabil Res. 2018 Jul;62(7):617-624. doi: 10.1111/jir.12500. Epub 2018 May 20.

PMID:
29781149
46.

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease.

Dekker AD, Vermeiren Y, Carmona-Iragui M, Benejam B, Videla L, Gelpi E, Aerts T, Van Dam D, Fernández S, Lleó A, Videla S, Sieben A, Martin JJ; Netherlands Brain Bank, Blesa R, Fortea J, De Deyn PP.

Alzheimers Dement (Amst). 2017 Nov 23;10:99-111. doi: 10.1016/j.dadm.2017.11.001. eCollection 2018.

47.

A Rare But Recognizable Cholestatic Liver Disease.

Ezcurra I, Fortea JI, Crespo J.

Gastroenterology. 2018 Sep;155(3):e17-e19. doi: 10.1053/j.gastro.2018.04.023. Epub 2018 Apr 24. No abstract available.

PMID:
29702116
48.

The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.

Dekker AD, Sacco S, Carfi A, Benejam B, Vermeiren Y, Beugelsdijk G, Schippers M, Hassefras L, Eleveld J, Grefelman S, Fopma R, Bomer-Veenboer M, Boti M, Oosterling GDE, Scholten E, Tollenaere M, Checkley L, Strydom A, Van Goethem G, Onder G, Blesa R, Zu Eulenburg C, Coppus AMW, Rebillat AS, Fortea J, De Deyn PP.

J Alzheimers Dis. 2018;63(2):797-819. doi: 10.3233/JAD-170920.

49.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
50.

Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients - An Atlas-Based Volumetric MRI Study.

Schönecker S, Neuhofer C, Otto M, Ludolph A, Kassubek J, Landwehrmeyer B, Anderl-Straub S, Semler E, Diehl-Schmid J, Prix C, Vollmar C, Fortea J; Deutsches FTLD-Konsortium, Huppertz HJ, Arzberger T, Edbauer D, Feddersen B, Dieterich M, Schroeter ML, Volk AE, Fließbach K, Schneider A, Kornhuber J, Maler M, Prudlo J, Jahn H, Boeckh-Behrens T, Danek A, Klopstock T, Levin J.

Front Aging Neurosci. 2018 Mar 15;10:45. doi: 10.3389/fnagi.2018.00045. eCollection 2018.

Supplemental Content

Loading ...
Support Center